2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2052

Preoperative Timing of Infliximab and Risk of Post-Operative Infection in a Medicare Cohort
Abstract Number: 2053

Prosthetic Joint Infection with Staphylococcus Aureus: Recurrence after Surgical Treatment in U.S. Veterans with and without Rheumatoid Arthritis
Abstract Number: 2054

Effect of Temporary Methotrexate Discontinuation on Efficacy of Seasonal Influenza Vaccination in Patients with Rheumatoid Arthritis: A Randomized Clinical Trial
Abstract Number: 2055

Myocardial Abnormalities Are Associated with Corrected QT Interval in Patients with Rheumatoid Arthritis without Cardiac Symptoms Assessed Using Cardiac Magnetic Resonance Imaging
Abstract Number: 2056

Choroid Plexus Infiltrates in Lupus Model (MRL/lpr) Mice Represent Tertiary Lymphoid Structures, Shedding Light on the Immunological Mechanisms of Neuropsychiatric Lupus
Abstract Number: 2057

TLR-7-Mediated Lupus Nephritis Flares Are Independent of Type I Interferon Signaling
Abstract Number: 2058

Ectonucleotidase-Mediated Protection of Lupus Mice from Exaggerated Immune Responses and Arterial Vasculopathy
Abstract Number: 2059

Serine/Arginine-Rich Splicing Factor 1 (SRSF1) Is a Novel Factor in T Cell Homeostasis and Its Selective Loss in T Cells Causes Autoimmunity and Lupus-like Nephritis
Abstract Number: 2060

Bim Suppresses the Development of SLE By Limiting Macrophage Inflammatory Responses
Abstract Number: 2061

Successful Treatment of Murine Lupus Nephritis with Helminths Related Tuftsin-Phosphorylcholine Compound and Its Effect on the Microbiota
Abstract Number: 2062

Increased Expression of Response Gene to Complement-32 in Kidney Biopsies from Patients with Lupus Nephritis
Abstract Number: 2063

Identification of Microrna Predictive of Outcome in Lupus Nephritis
Abstract Number: 2064

Blood and Kidney Molecular Profiles Distinguish Subjects with Lupus Nephritis from Other Kidney Disorders
Abstract Number: 2065

Platelet FcγRIIa Polymorphism H131R Associates with Subclinical Atherosclerosis and Increased Platelet Activity in SLE
Abstract Number: 2066

Anti-Ds-DNA Antibodies Regulate Atherothrombosis in Systemic Lupus Erythematosus through the Induction of Netosis, the Prothrombotic and Proinflammatory Activities of Monocytes and the Endothelial Activation

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].